Related Experiment Video
Updated: Jul 22, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Pneumococcal conjugate vaccine for young children
1Department of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.
The pneumococcal conjugate vaccine (PCV) significantly reduces invasive pneumococcal disease. This vaccine shows high efficacy in infants and children, preventing serious infections like meningitis and pneumonia.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- Streptococcus pneumoniae causes significant morbidity and mortality from meningitis, pneumonia, and otitis media annually in the US.
- Pneumococcal conjugate vaccine (PCV) was introduced in 2000 to target prevalent serotypes responsible for invasive infections in young children.
Purpose of the Study:
- To evaluate the efficacy of the pneumococcal conjugate vaccine against invasive pneumococcal disease.
- To outline the recommended vaccination schedule and target populations for PCV.
Main Methods:
- A large randomized, double-blind, controlled trial was conducted to assess vaccine efficacy.
- Follow-up analysis was performed eight months post-trial to determine sustained efficacy.
Main Results:
- The PCV demonstrated 100% efficacy against invasive pneumococcal disease in the primary analysis.
- Follow-up analysis confirmed 94% efficacy against invasive disease for the targeted serotypes.
- The standard infant vaccination schedule includes doses at 2, 4, 6, and 12-15 months of age.
Conclusions:
- The pneumococcal conjugate vaccine is highly effective in preventing invasive pneumococcal disease in children.
- Routine infant vaccination and catch-up vaccination for at-risk children are recommended by the American Academy of Family Physicians.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children
Streptococcal Pharyngitis
Pneumonia I: Introduction